This trial is evaluating whether TNO155 will improve 3 primary outcomes and 13 secondary outcomes in patients with Gastrointestinal Stromal Tumors. Measurement will happen over the course of 1 year.
This trial requires 185 total participants across 2 different treatment groups
This trial involves 2 different treatments. TNO155 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Carcinoma, NSCLC, describes lung tumors consisting of mostly or predominantly malignant cells. Small cell carcinoma of the lung is a sub-type of NSCLC that is rarely recognized by clinicians because of its fast growth pattern and rapid spread." - Anonymous Online Contributor
"A history of smoking and COPD are risk factors for lung cancer, which could have been prevented by early detection. More research on occupational lung disease is indicated." - Anonymous Online Contributor
"Lung cancer has been cured mostly by systemic anticancer therapy. However, in a small percentage of cases, the cancer may relapse. Therefore, alternative treatments to chemotherapy have been used to attempt cancer cure. In patients with advanced non-small-cell lung cancer, a combination of chemoradiation and chemotherapy is the currently recommended treatment. Although there are several clinical trials focusing on chemo-radiation or chemoradiation, few studies have documented that treatment result more effective. Considering that the treatment of patients with advanced NSCLC is often not curative, alternative therapeutic strategies are necessary. In the field of oncology, cancer cure or cure of cancer is a goal of many research efforts." - Anonymous Online Contributor
"About 140,000 people become newly diagnosed with carcinoma of the lung each year. Tobacco smoking is still a major cause of death from lung cancer." - Anonymous Online Contributor
"The majority of lung cancer cases are due to squamous carcinoma of other organs. If a primary site is missed, then the majority of patients still have squamous cell carcinoma. Other factors influencing risk are age, family history, and a number of genetic conditions. Smoking causes the majority of squamous cell carcinomas, but the role of genetics and the environment could not be excluded. Histological subtype shows great heterogeneity with respect to risk factors and prognosis." - Anonymous Online Contributor
"Treatment of small-cell [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) with chemotherapy alone increases life expectancy from less than three months to 12 months, but with chemotherapy, the cancer is unlikely to come back. Chemotherapy also gives a small survival advantage when used in combination with surgery. If chemotherapy is given by itself, the cancer is likely to be cured. For non-small-cell lung cancer, chemotherapy improves the overall survival rate, but does this only by a small percentage point relative to surgery. Radiotherapy increases the overall survival rate for non-small-cell lung cancer by only a small percentage point. For both small- and non-small-cell lung cancer, surgery should always be used in combination with chemotherapy or radiotherapy." - Anonymous Online Contributor
"Carcinoma, non-small-cell lung runs in families. The disease is associated with an increased prevalence of smoking and other exposures, including the use of certain psychoactive drugs, suggesting that genetic susceptibility has a contribution." - Anonymous Online Contributor
"Overall survival in NSCLC for patients who received tno155 was comparable to those receiving the standard of care. The overall survival benefit of tno155 in this study was not consistent with current recommendations for NSCLC. The efficacy of tno155 may be related to the low percentage of patients who smoked. This pilot study showed significant improvements in QoL, which are important for treating cancer and are important for NSCLC as well. In this population, tno155 led to improved symptoms and increased physical function (e.g., walking distance). tno155 also helped to improve patients QoL compared to the standard of care." - Anonymous Online Contributor
"Overall, results of the current study demonstrated that tno155 had no measurable effects on overall survival. However, when used according to the guidelines, tno155 may have been more potent than conventional cyclophosphamide treatment, even in the presence of advanced or recurrent CLL." - Anonymous Online Contributor
"If the patient is willing to comply with the proposed trial and the clinician is confident that the therapy will be efficacious, then patients should be offered the option of clinical trial treatment." - Anonymous Online Contributor
"We have demonstrated the potential for this drug to be a useful chemotherapeutic agent against NSCLC. Our preclinical and clinical studies, if successful, would be [conducted in Phase I and II trials. However, tno155 can be administered as a chemotactic agent with the potential to act as a potent immunostimulant by targeting its natural receptor, GRP-56 (a member of the C1q sub-family of immunoglobulins)." - Anonymous Online Contributor
"Allogeneic CD44s-knockout tumor cell lines are sensitive to Tno155 treatment irrespective of their tumor phenotype, suggesting that the combination of this gene with conventional immune checkpoint agents may have potent antitumor, antitumor immune checkpoint activity at nontargeted sites." - Anonymous Online Contributor